Erlotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is an orally active agent for advanced NSCLC and pancreatic cancer [3, 15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.